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patients using CSII and CGM; and 5)Results are more sensitive to reimbursement for 
routine physician care and lifestyle modification services. ConClusions: 1) Seven 
American professional societies comprising the Diabetes Working Group (DWG) 
concur delivering high-quality, guideline-based diabetes care unrealistic given cur-
rent care and payment paradigms; 2) DWG recommends alternative approaches 
in 3 areas: care management, payment reform, and workforce supply, to mitigate 
increasing medical and financial impact of this epidemic chronic illness; 3) Model 
can be used internationally to support public policy efforts.
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objeCtives: Evaluate treatment patterns of Type 2 diabetes (T2D) patients initiat-
ing glucagon-like peptide-1 receptor agonists (GLP1) or insulin glargine in Germany 
(GE) and UK. Methods: Adult T2D patients initiating exenatide twice-daily (exBID), 
liraglutide (LIRA) or glargine (1/10-12/11), or exenatide once-weekly (exQW) (1/10-
6/12), were identified using the IMS LifeLink™ EMR-EU databases (exQW in GE 
only). Therapy initiation date was termed ‘index date’. Eligible patients were naïve 
to index therapy class and had ≥ 180 days pre- and ≥ 360 days post-index data (180 
post-index exQW only). Treatment modification was evaluated over 180-day and 
total post-index period. Patients were required to have non-missing prescription 
data. Results: 6,171 GE (300 exBID/174 exQW/906 LIRA/4,791 glargine) and 1,042 UK 
(249 exBID/306 LIRA/487 glargine) patients were included. Approximately half were 
male (GE/UK% 53.9/51.9). At index, mean age in GE/UK was 57.6/57.6 among GLP1 
initiators; 67.4/63.1 among glargine initiators. Incidence of treatment modification 
(discontinuation, switch or augmentation) over 180-day post-index varied by treat-
ment and country (GE/UK,%): exBID (58.0/41.4), LIRA (54.1/39.2), exQW (40.8/NA), 
glargine (13.7/29.2). Augmentation as first modification was rare among exBID and 
LIRA patients (GE/UK,% of those with modification); 11.5/6.8 and 10.0/7.5, respec-
tively, compared to exQW (26.8/NA) and glargine (66.1/45.1). Discontinuation rates 
(i.e., stopping index therapy without switch to a new therapy) were higher than 
switching rates throughout the 180-day period for GLP1 and glargine users (GE/UK,% 
of those with modification): GLP1 74.4/75.3 discontinuation & 13.6/17.5 switch; glar-
gine 32.9/52.8 discontinuation and 1.1/2.1 switch. Using all available post-index data, 
mean follow-up was (GE/UK, months): exBID 24.5/25.6, LIRA 24.0/21.8, exQW 10.6/
NA, and glargine 24.4/25.4; proportions with treatment modification were (GE/UK,%): 
exBID 91.0/81.5, LIRA 80.1/71.6, exQW 57.5/NA, glargine 69.8/72.1. ConClusions: 
Treatment patterns varied among GLP1 and glargine patients. Longer-term data 
would be useful to further elucidate practice patterns associated with these medi-
cines, particularly exQW.
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objeCtives: The United Arab Emirates (UAE) has among the highest prevalence 
(25%) of type 2 diabetes mellitus (T2DM) globally; however, few data are available 
on how patients are managed in clinical practice. The objective was to characterize 
recent treatment patterns among T2DM patients in Dubai. Methods: Charts from 
T2DM patients aged ≥ 18 years that visited the Dubai Hospital between October 
2009 and March 2010 (enrolment period) were systematically sampled until the tar-
get (n= 250) was reached. Treatment data from enrolment to September 2011 were 
abstracted from patient charts, as well as treatments received before enrolment. 
Treatment regimens, their frequency of use, and the number of switches (drug 
replacement/removal/addition) over the study period were calculated. Analyses 
were stratified by T2DM duration, and data for those recently-diagnosed (< 5 years; 
n= 29) and with longstanding disease (≥ 20 years; n= 67) are presented. Results: 
Mean age at enrolment was 58 years (SD: 12 years), 33% were male, and mean 
T2DM duration was 14 years (SD: 8 years). At enrolment, 74% of patients had 
received prior insulin treatment (recently-diagnosed: 55%; longstanding disease: 
84%). During the study period, the most common regimens were insulin+oral 
combination therapy (55%) and oral combination therapy (39%). Overall, 67% 
received any insulin therapy during the study period (recently-diagnosed: 45%; 
longstanding disease: 87%). By study end, 78% had received insulin therapy at 
any time (recently-diagnosed: 62%; longstanding disease: 88%). On average, T2DM 
patients had two treatment switches; little variation was seen by T2DM dura-
tion. ConClusions: Most patients had longstanding T2DM and received treat-
ment with insulin. Patients had an average of two treatment switches over the 
relatively short study period, indicating modification was attempted to improve 
T2DM control. Novel therapies may improve clinical outcomes among T2DM 
patients and this study provides valuable baseline data with which to compare 
the effectiveness of new T2DM treatments in Dubai.
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The increasing budgetary constraints faced by health care payers have made the 
access decision increasingly complex and decentralized processes a growing trend. 
Thus, demonstration of new health technologies value has become critical to ensure 
patients’ access to innovation.objeCtives: To identify the most important value 
messages within decision making process in the treatment of Type 2 Diabetes 
Mellitus (T2DM) among General Practitioners (GP) coordinating Primary Care 
Centers. Methods: Regional meetings based on Health Economics training held 
(during 2013) with GPs, including the presentation of a cost-effectiveness analysis of 
vildagliptin vs sulphonilureas (SU) and a budget impact tool that enables the estima-
tion of meaningful impacts of T2DM. Two surveys were developed to be applied at 
beginning and end of training to characterize the learning insights and identify the 
factors considered in the decision process. Results: Partial results based on a 51 
GPs sample are presented. The positive impact of the training in HE concepts was 
statistically significant (p= 0.000) with an 89.4% average rate of correct answers. More 
than 50% of GPs considered the increasing prevalence of T2DM, cost of macrovascu-
lar and microvascular complications and the impact of hipoglycaemias in patients’ 
quality of life (QoL) and costs, as the most important factors in the decision process. 
The key decision factor to use vildagliptin is the improvement of patients’ QoL. The 
use of SU is explained due to its fast response, mainly in patients with Hb1Ac level 
above 7.5%. Majority of GPs (87.5%) chose vildagliptin as the preferred therapeutic 
for T2DM patients not controlled with metformin. ConClusions: This analysis 
demonstrated that both epidemiological and economic factors are important at 
local decision process. Clinically, patients’ QoL is the most relevant achievement. 
Most GPs prefer vildagliptin to control T2DM, considering QoL improvements its 
greatest benefit.
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objeCtives: Despite the high prevalence (25%) of type 2 diabetes mellitus (T2DM) in 
the United Arab Emirates (UAE), few data are available on the types and quality of care 
administered. Quality of care is an important determinant of whether clinical targets 
can be met, and serious complications avoided. The objective was to estimate the 
proportion of T2DM patients receiving recommended monitoring of clinical measures 
in Dubai, over one year. Methods: Charts from T2DM patients aged ≥ 18 years that 
visited the Dubai Hospital between October 2009 and March 2010 (enrolment period) 
were systematically sampled until the target (n= 250) was reached. Quality of care 
was assessed from April 2010 to March 2011, adapted from the United States (US) 
Healthcare Effectiveness Data and Information Set (HEDIS) Comprehensive Diabetes 
Care measures. Measures included: glycosylated haemoglobin (HbA1c) screening, 
control (< 8%) and poor control (> 9%); low-density lipoprotein (LDL) screening and 
control (< 100mg/dL); blood pressure (BP) control (< 140/90mmHg); retinopathy screen-
ing; and medical attention for nephropathy. Patients were classified as having control 
based on their latest test in the period. Results: Mean age at enrolment was 58 years 
(standard deviation (SD): 12 years), 33% were male, and mean T2DM duration was 14 
years (SD: 8 years). Over the 12-month period, 98% underwent HbA1c screening (54% 
had control and 26% displayed poor control); 90% underwent LDL screening (64% 
had control); 43% had BP control; 32% had retinopathy screening; and 16% attention 
for nephropathy. Two-hundred and eleven patients (84%) were screened for BP, LDL 
and HbA1c measures over the period. ConClusions: Guideline monitoring was 
conducted for most patients; rates of compliance were comparable to or higher than 
US benchmarks for HbA1c and LDL monitoring. Greater understanding of the factors 
leading to high adherence to the guidelines would be useful for other areas of preven-
tive care, and other hospitals and jurisdictions.
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objeCtives: 1) Build economic model to estimate resources to deliver current 
standards of care to US diabetes patients, and 2) Evaluate provider costs to meet 
standards, assess patient outcomes specified in guidelines relative to reimburse-
ment. Methods: Build model: 1) Integrate 3 national standard sets (ADA, AACE, 
and TES) into 28 consolidated standards of optimal care; 2) Develop provider matrix 
for rendering care; 3) Draft 6 clinical vignettes: 3 each T1DM and T2DM; 4) Convene 
3 multidisciplinary panels of 4-7 care professionals; with facilitator, estimate mini-
mum/maximum time to achieve care standards/patient type – baseline/best cases; 
5) Convene separate panel estimating time to start/follow patients using CSII or 
CGM; 6) Multiply provider time by average wage and overhead amounts to deter-
mine visit cost; 7) Map activities to CPT and HCPCS billing codes and payment 
rates; 8) Compute reimbursement per expected payer mix; and 9) Note gaps in 
reimbursement compared to costs on unit and total basis. Populate model; perform 
analytics: Repeat Steps 4-9 with data from national provider survey and national 
database. Results: 1) Baseline scenarios show provider costs exceed reimburse-
ments for all type patients; best case indicates same in 5 of 6 scenarios; 2) In dif-
ferent scenarios costs of treating adults exceed reimbursement by > $750,000 per 
year; practices would require 19%-64% increase to breakeven; 3) In pediatric prac-
tice, costs exceed reimbursement by > $471,000 per year; 4) Gaps are increased for 
